Mallinckrodt Confirms Receipt of Stannsoporfin Complete Response Letter

STAINES-UPON-THAMES, United Kingdom, Aug. 22, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, confirmed today that it has received a Complete Response Letter from the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news